Input from community, message boards, and engagement survey
Like women, men can inherit BRCA mutations. NCCN guidelines recommend genetic counseling and testing for men with a personal or family history suggestive of HBOC. Men with BRCA mutations can pass their mutation on to sons or daughters. Each child has a 50% chance of inheriting their father's mutation. Men who inherit a BRCA mutation have an increased lifetime risk for certain cancers which is higher than the average man, but not as high as women with mutations. Despite this information, a small number of men who meet guidelines undergo genetic risk assessment.
Recently there has been increased attention to research that men with BRCA mutations tend to develop a more aggressive form of prostate cancer than men without mutations, leading to increased interest in screening high-risk men for prostate cancer to detect it early. Additional there is interest in BRCA testing for men with aggressive prostate cancer and new clinical trials are looking at treatment with platinums and/or PARP inhibitors in men with mutations.
Along with this emerging research, there is increasing interest in identifying and testing high-risk men for inherited mutations.
Our Steering Committee and Research Work Group gave this study a prioritization score of 2.62 out of 4 points, meaning this is a medium-priority study.
Our Executive Committee and research team considered the feasibility of developing this study through ABOUT as medium.
Our Steering Committee prioritizes questions based on four parameters on a scale from 1-4. Here are the average scores:
Our Executive Committee scored feasibility as medium based on the following considerations:
Kote-Jarai Z, Leongamornlert D, et. al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer, 105(8): p. 1230-1234. October, 2011.
Mitra AV, Bancroft EK, et. al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. British Journal of Urology International. Volume 107(1), p. 28-39. January, 2011.
Edwards SM, Evans DG, et. al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer. 2010 Sep 27;103(6):p. 918-24. September, 2010.
Previvors/High risk people
People with a BRCA mutation
People with an ATM, PALB2, PTEN, or other mutation that increases cancer risk
People with Lynch Syndrome
People at high risk for breast cancer
People at high risk for ovarian cancer
People who are newly diagnosed with cancer